Table 1

Baseline characteristics

All participants(n = 813)
Age (years)51.8 ± 9.8
Sex, men/women (n)627/186
BMI (kg/m2)24.0 ± 3.3
Waist circumference (cm)85.9 ± 8.5
Amylase (IU/L)72.1 ± 27.7
Creatinine (mg/dL)0.74 ± 0.16
AST (units/L)24.6 ± 14.3
ALT (units/L)27.4 ± 18.4
GGT (units/L)55.1 ± 59.0
Albumin (g/dL)4.3 ± 0.23
FPG (mg/dL)91.9 ± 9.7
HbA1c (%)5.2 ± 0.32
HbA1c (mmol/mol)33 ± 3.5
IFG, n (%)159 (19.6)
Pancreas attenuation (HU)46.0 ± 9.5
Liver attenuation (HU)62.9 ± 9.3
Family history of DM, n (%)144 (17.7)
Dyslipidemia, n (%)397 (48.8)
Hypertension, n (%)193 (23.7)
Alcohol intake ≥20 g/day241 (29.6)
Current smoker, n (%)268 (33.3)
Physical exercise, n (%)163 (20.0)
  • Continuous data are expressed as mean ± SD, unless otherwise indicated. Pancreas attenuation indicates the mean attenuation of the pancreatic head, body, and tail on an unenhanced CT scan. Liver attenuation indicates the mean attenuation of the hepatic left lobe, anterior segment, and posterior segment. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DM, diabetes mellitus; FPG, fasting plasma glucose; GGT, γ-glutamyltransferase; IFG, impaired fasting glucose.